Currently, place a few drops in your eyes and regain the ability to read without glasses for up to 10 hours. That is the proposal of LENZ, the first aceclidine-based eye drops approved by the FDA to treat presbyopia, a condition that affects virtually everyone after the age of 45.

Developed by the pharmaceutical company LENZ, it promises to correct near vision without compromising distance vision, marking an unprecedented advance in the treatment of this visual limitation. Presbyopia is a currently inevitable consequence of aging, making simple tasks like reading a label or book a constant challenge.

Until now, glasses and contact lenses were the most common solutions, but LENZ arrives to change this panorama. Its operation is based on a gentle contraction of the pupil, creating the so-called "pinhole" effect, similar to the closure of the diaphragm of a camera that improves the focus of close objects without causing distortions in distant vision.

Unlike previous eye drops, it does not overstimulate the auxiliary muscle, avoiding annoying side effects such as pain in the eyebrows or unusual risks for the retina. The effectiveness of bis was proven in three randomized, double-blind phase two studies involving hundreds of participants in more than 30,000 days of recorded use with no miscellaneous to serious events.

In all tests, volunteers reported a significant improvement in reading and near vision activities, with a rapid onset of the effect and an average duration of up to 10 hours, in addition to the practical impact for millions of people, specialists believe that the approval by the FDA represents a milestone for modern ophthalmology.

Optometrists and ophthalmologists will be able to offer a safe and highly effective treatment as early as the fourth quarter of 2025, capable of quickly becoming the new standard for near vision correction.